Pepti Tirzepatide Review: $199 Flat, and One Ladder We Could Not Reconcile (2026)

Pepti sells injectable compounded tirzepatide at $199 a month, and says that price is the same at 2.5 mg and at 15 mg — no dose-indexed increase, cancel whenever you like. That is one of the better tirzepatide numbers we track, and dose-flat pricing is the single most valuable term a compounded GLP-1 seller can offer. There is also a second tirzepatide price ladder sitting in Pepti's own production data that says something else entirely, and we could not determine which one a real checkout charges. This page carries no outbound link; every figure below was pulled from Pepti's own JavaScript bundle in August 2026.

The published tirzepatide price

Injectable tirzepatide is $199 a month on a subscription, or $249 as a one-time order. Injectable semaglutide is $99 and $124. Oral tirzepatide is $399 a month; oral semaglutide is $249. The one-time price is exactly the subscription price times 1.25 across the whole catalog — 99 becomes 124, 199 becomes 249, 399 becomes 499 — which is at least a rule rather than a mood.

The subscription is the month-to-month rung. Pepti's subscription terms let you cancel at any time, effective at the end of the cycle, and pause for up to ninety days. There is no minimum term and no prepay tier, so there is no prepay-as-monthly trap to unpick. On its face this is a clean, cheap, cancellable tirzepatide plan.

The ladder we could not reconcile

Pepti's tirzepatide page ships a server payload containing a `doseOptions` array. It prices tirzepatide by dose:

Nothing renders it. We searched every JavaScript chunk the site downloads for the code that would consume that array and found zero occurrences. Meanwhile the cost page states, in as many words, that all doses share one flat monthly price and that price is $199 for tirzepatide. Three other cross-sell surfaces repeat the flat figure. The catalog object the page actually reads carries the flat figure.

So which one bills you? We do not know, and we are not going to guess. The checkout endpoint accepts POST only and returns 405 to anything else, so there was no way to get a price out of it without submitting a real intake. What we can say precisely is this: the rendered price is $199, five independent surfaces agree on $199, and a per-dose ladder averaging roughly three times that number is sitting in the data the page was built from. A dead array is usually a stale artifact somebody forgot to delete. Usually.

What to do with that. Before you pay Pepti anything, get the price for your dose in writing, and get it in writing again when you titrate up. If the flat price is real, that costs you one email. If it is not, that email is the difference between $199 and $549 a month at 15 mg — and 15 mg is where most people who respond to tirzepatide end up. Our tirzepatide dosage chart shows how quickly the ladder climbs.

Thirty-six states, or fifty

Pepti publishes a list of 36 states it ships to, and publishes it in four separate places — its shipping page, its state-availability page, its providers page and the homepage title. Its terms of service say the service is available in 50 states. Four surfaces against one, with an actual enumerated list on the side of thirty-six: treat 36 as the operative number. The states named are AL, AZ, AR, CA, CO, CT, DE, FL, GA, HI, IL, KS, KY, LA, MD, MA, MI, MN, MS, MO, MT, NE, NM, NY, NC, ND, OH, OK, PA, RI, SD, TN, TX, VT, VA and WA. At-home blood panels ship to all fifty.

When your card is charged

Same pattern, smaller stakes. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake. The refund policy is the operative document, so plan on being charged first and refunded — in five to ten business days — if you are turned down. Nothing is refundable once medication ships, and canceling mid-cycle is not prorated.

What else is on the shelf, and what to walk past

Sixty-eight products across injectables, oral drops, nasal sprays, recovery peptides, anti-aging peptides and a small hormone line. Three of them belong in a warning rather than a catalog: retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any jurisdiction, in any form — it is still in trials, and a compounded version of an unapproved investigational molecule is a category of risk distinct from compounded tirzepatide. We explain the difference in retatrutide vs tirzepatide. Whatever Pepti's tirzepatide is worth, none of those three should factor into it.

Who prescribes, and who compounds

Two prescribers are named with full biographies: Dr. Gene Lee, MD, family medicine, medical director, and Dr. Laeeq Butt, MD MBA, internal medicine, chief medical officer, with the states each is licensed in listed out. That is good disclosure with one hole in it — neither NPI is published, so neither registration can be checked against the national provider registry. The Edit publishes its medical director's NPI and it resolves; see The Edit for what that looks like when it is done fully.

The pharmacy is never named. The site says "independent FDA-registered 503A or 503B compounding pharmacies," which is the standard formulation for telling you nothing. The corporate entity is pepti LLC at a Newark, Delaware address that is a well-known registered-agent suite rather than an operating site — common, and not itself damning, but it means the address on the terms page is not a place where anything happens.

The regulatory screen

The trading name and the legal entity both returned zero company-column matches in the FDA's live warning-letter index in August 2026.² Worth noting what surrounds them: a bare search for "pepti" returns forty-five letters, several of them to peptide sellers that FDA has written to. Pepti is not among them. The screen carried a positive control that correctly returned a real February 2026 letter to an unrelated telehealth seller on every pass,³ so the zero is a finding rather than a broken query.

Brand versus compounded

Everything here is compounded. Compounded tirzepatide is pharmacy-made, is not an FDA-approved finished drug, and was not the product used in the trials that make the molecule worth taking. See is compounded tirzepatide still legal in 2026. The trial evidence itself — roughly 15% to 21% average body-weight loss over 72 weeks in SURMOUNT-1⁴, about 20% against semaglutide's 14% in SURMOUNT-5⁵ — belongs to the brand molecule at approved doses, and is laid out in our tirzepatide evidence guide.

The honest verdict

If $199 is the price, Pepti is one of the strongest tirzepatide offers in our ranking: flat at every dose, cancellable, no prepay, named prescribers, a published state list. If $199 is not the price, it is one of the worst, because the alternative sitting in its own data is $549 at the dose most people finish at. We are not in a position to tell you which, and any site that tells you confidently has not looked at the same thing we did. Get your dose priced in writing before you pay, and again when you titrate. Then compare it against Trellis Vitality, which also lists tirzepatide at $199 but publishes an ordinary rung table with nothing hiding behind it, and against the rest of the field in our tirzepatide price index and the ranked best tirzepatide providers ranking.